BENJAMIN EDWARDS INC - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.

Quarter-by-quarter ownership
BENJAMIN EDWARDS INC ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$23
-17.9%
504
+2.6%
0.01%
-28.6%
Q2 2023$28
+12.0%
491
-12.0%
0.01%
+16.7%
Q1 2023$25
+19.0%
558
+5.7%
0.01%0.0%
Q4 2022$21
-99.9%
528
+25.4%
0.01%
-25.0%
Q3 2022$28,000
-6.7%
421
-15.6%
0.01%
-11.1%
Q2 2022$30,0000.0%499
+4.0%
0.01%0.0%
Q1 2022$30,000
-16.7%
480
+2.1%
0.01%
-25.0%
Q4 2021$36,000
-18.2%
470
+18.7%
0.01%
-55.6%
Q3 2021$44,000
-33.3%
396
-3.4%
0.03%
-40.0%
Q2 2021$66,000
+13.8%
410
-14.2%
0.04%
+2.3%
Q1 2021$58,000
-30.1%
478
-12.3%
0.04%
-31.2%
Q4 2020$83,000
+27.7%
545
-29.9%
0.06%
+18.5%
Q3 2020$65,000
+20.4%
778
+6.6%
0.05%
+20.0%
Q2 2020$54,000
+74.2%
7300.0%0.04%
+40.6%
Q1 2020$31,000
-18.4%
730
+17.6%
0.03%
-59.0%
Q4 2019$38,000
+65.2%
621
+9.5%
0.08%
+56.0%
Q3 2019$23,000
-11.5%
567
+3.8%
0.05%
-20.6%
Q2 2019$26,000
+160.0%
546
+96.4%
0.06%
+31.2%
Q1 2019$10,0002780.05%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q1 2022
NameSharesValueWeighting ↓
Gilfoyle Management LLC 150$6,37612.96%
Versant Venture Management, LLC 498,558$22,629,54812.03%
NEA Management Company, LLC 1,587,854$72,072,6935.57%
ARK Investment Management 7,163,118$325,133,9132.49%
Nikko Asset Management Americas, Inc. 3,465,470$157,263,0291.88%
Integral Health Asset Management, LLC 275,000$12,482,2501.73%
Merlin Capital, Inc 9,092$412,6861.54%
Del-Sette Capital Management, LLC 33,977$1,542,2161.52%
Green Alpha Advisors, LLC 34,880$1,583,2031.22%
Ikarian Capital, LLC 2,039$9,255,0211.11%
View complete list of CRISPR THERAPEUTICS AG shareholders